ipamorelin dosing guidelines dosage for muscle building cjc 1295 and blend cjc-1295 ipamorelin bodybuilding Buy CJC-1295 & Ipamorelin Blend (10mg) Ipamorelin ارينسيا تي اكس ايه Changes in levels of Dosage:10mg
Changes in levels of the antioxidant glutathione in brain and blood across the age span of healthy adults: A systematic review - PMC
The subsequent C-S bond cleavage produces a PLP-based adduct ( 19 ) and a sulfenic intermediate of hercynine ( 12 ), which is released from the active site into the solvent environment
ارينسيا تي اكس ايه
Dosage:10mg
Species 0.000 description 3 OPVHBDHPGVKMBM-UHFFFAOYSA-N N-[2-(4-hydroxyphenyl)ethyl]-2-sulfanylacetamide Chemical compound OC1=CC=C(CCNC(=O)CS)C=C1 OPVHBDHPGVKMBM-UHFFFAOYSA-N 0.000 description 3 BAARASVZOMIZMH-UHFFFAOYSA-N N-[2-(4-hydroxyphenyl)ethyl]-2-tritylsulfanylacetamide Chemical compound OC1=CC=C(CCNC(CSC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)=O)C=C1 BAARASVZOMIZMH-UHFFFAOYSA-N 0.000 description 3 241000700159 Rattus Species 0.000 description 3 229920002472 Starch Polymers 0.000 description 3 QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3 HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3 239000003963 antioxidant agent Substances 0.000 description 3 230000006907 apoptotic process Effects 0.000 description 3 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3 230000004071 biological effect Effects 0.000 description 3 210000004556 brain Anatomy 0.000 description 3 HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 3 150000001721 carbon Chemical group 0.000 description 3 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3 208000026106 cerebrovascular disease Diseases 0.000 description 3 239000002738 chelating agent Substances 0.000 description 3 125000000392 cycloalkenyl group Chemical group 0.000 description 3 XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3 235000018417 cysteine Nutrition 0.000 description 3 230000003247 decreasing effect Effects 0.000 description 3 238000009795 derivation Methods 0.000 description 3 238000011161 development Methods 0.000 description 3 206010012601 diabetes mellitus Diseases 0.000 description 3 125000004663 dialkyl amino group Chemical group 0.000 description 3 230000003292 diminished effect Effects 0.000 description 3 150000002019 disulfides Chemical class 0.000 description 3 229940079593 drug Drugs 0.000 description 3 238000003379 elimination reaction Methods 0.000 description 3 239000003480 eluent Substances 0.000 description 3 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3 125000001153 fluoro group Chemical group F* 0.000 description 3 229920000159 gelatin Polymers 0.000 description 3 239000008273 gelatin Substances 0.000 description 3 235000019322 gelatine Nutrition 0.000 description 3 235000011852 gelatine desserts Nutrition 0.000 description 3 230000036541 health Effects 0.000 description 3 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 3 239000012442 inert solvent Substances 0.000 description 3 239000003112 inhibitor Substances 0.000 description 3 238000002347 injection Methods 0.000 description 3 239000007924 injection Substances 0.000 description 3 239000000543 intermediate Substances 0.000 description 3 238000005342 ion exchange Methods 0.000 description 3 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3 230000000670 limiting effect Effects 0.000 description 3 239000007788 liquid Substances 0.000 description 3 208000002780 macular degeneration Diseases 0.000 description 3 238000005259 measurement Methods 0.000 description 3 239000012528 membrane Substances 0.000 description 3 230000002107 myocardial effect Effects 0.000 description 3 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3 230000036961 partial effect Effects 0.000 description 3 230000037361 pathway Effects 0.000 description 3 230000010412 perfusion Effects 0.000 description 3 239000000546 pharmaceutical excipient Substances 0.000 description 3 239000001267 polyvinylpyrrolidone Substances 0.000 description 3 230000003389 potentiating effect Effects 0.000 description 3 150000003254 radicals Chemical class 0.000 description 3 239000007843 reactive sulfur species Substances 0.000 description 3 230000010282 redox signaling Effects 0.000 description 3 230000009467 reduction Effects 0.000 description 3 238000011160 research Methods 0.000 description 3 239000011347 resin Substances 0.000 description 3 229920005989 resin Polymers 0.000 description 3 230000002441 reversible effect Effects 0.000 description 3 MNOALXGAYUJNKX-UHFFFAOYSA-N s-chloro chloromethanethioate Chemical compound ClSC(Cl)=O MNOALXGAYUJNKX-UHFFFAOYSA-N 0.000 description 3 229910052710 silicon Inorganic materials 0.000 description 3 238000001228 spectrum Methods 0.000 description 3 238000010186 staining Methods 0.000 description 3 238000006467 substitution reaction Methods 0.000 description 3 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3 DFVRUHANEXOZGT-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(methylamino)ethyl]carbamate Chemical compound CNCCN(C)C(=O)OC(C)(C)C DFVRUHANEXOZGT-UHFFFAOYSA-N 0.000 description 3 125000005309 thioalkoxy group Chemical group 0.000 description 3 230000035899 viability Effects 0.000 description 3 229920002554 vinyl polymer Polymers 0.000 description 3 HBQGCOWNLUOCBU-ONEGZZNKSA-N (e)-4-(ethylamino)-4-oxobut-2-enoic acid Chemical compound CCNC(=O)\C=C\C(O)=O HBQGCOWNLUOCBU-ONEGZZNKSA-N 0.000 description 2 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2 KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2 AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 2 VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2 QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2 QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2 QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2 241000894006 Bacteria Species 0.000 description 2 208000035143 Bacterial infection Diseases 0.000 description 2 241000283690 Bos taurus Species 0.000 description 2 208000014644 Brain disease Diseases 0.000 description 2 CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2 COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2 OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2 UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2 208000031229 Cardiomyopathies Diseases 0.000 description 2 206010058892 Carnitine deficiency Diseases 0.000 description 2 HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 2 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 2 FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2 FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2 RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2 208000032274 Encephalopathy Diseases 0.000 description 2 241000283086 Equidae Species 0.000 description 2 KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2 208000024412 Friedreich ataxia Diseases 0.000 description 2 WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2 HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2 241000282412 Homo Species 0.000 description 2 208000023105 Huntington disease Diseases 0.000 description 2 CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2 206010020772 Hypertension Diseases 0.000 description 2 DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2 239000007836 KH2PO4 Substances 0.000 description 2 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 2 WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2 GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 description 2 201000009035 MERRF syndrome Diseases 0.000 description 2 208000035719 Maculopathy Diseases 0.000 description 2 208000014413 Maternally-inherited diabetes and deafness Diseases 0.000 description 2 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 description 2 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2 241001529936 Murinae Species 0.000 description 2 WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2 238000005481 NMR spectroscopy Methods 0.000 description 2 229910002651 NO3 Inorganic materials 0.000 description 2 NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2 206010061323 Optic neuropathy Diseases 0.000 description 2 KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2 OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2 239000002202 Polyethylene glycol Substances 0.000 description 2 ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2 206010063897 Renal ischaemia Diseases 0.000 description 2 241000282887 Suidae Species 0.000 description 2 FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2 GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2 YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2 238000002835 absorbance Methods 0.000 description 2 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2 230000004913 activation Effects 0.000 description 2 125000004442 acylamino group Chemical group 0.000 description 2 125000001931 aliphatic group Chemical group 0.000 description 2 125000000278 alkyl amino alkyl group Chemical group 0.000 description 2 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2 238000000540 analysis of variance Methods 0.000 description 2 230000010100 anticoagulation Effects 0.000 description 2 210000000709 aorta Anatomy 0.000 description 2 229910052786 argon Inorganic materials 0.000 description 2 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2 208000029560 autism spectrum disease Diseases 0.000 description 2 208000022362 bacterial infectious disease Diseases 0.000 description 2 230000008901 benefit Effects 0.000 description 2 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2 230000008827 biological function Effects 0.000 description 2 230000008512 biological response Effects 0.000 description 2 230000000903 blocking effect Effects 0.000 description 2 BEWYHVAWEKZDPP-UHFFFAOYSA-N bornane Chemical compound C1CC2(C)CCC1C2(C)C BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 2 239000011575 calcium Substances 0.000 description 2 229910052791 calcium Inorganic materials 0.000 description 2 239000001110 calcium chloride Substances 0.000 description 2 229910001628 calcium chloride Inorganic materials 0.000 description 2 235000013877 carbamide Nutrition 0.000 description 2 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2 239000001768 carboxy methyl cellulose Substances 0.000 description 2 210000000803 cardiac myoblast Anatomy 0.000 description 2 239000000969 carrier Substances 0.000 description 2 230000030833 cell death Effects 0.000 description 2 230000003833 cell viability Effects 0.000 description 2 230000001413 cellular effect Effects 0.000 description 2 239000003153 chemical reaction reagent Substances 0.000 description 2 208000024825 childhood disintegrative disease Diseases 0.000 description 2 238000000576 coating method Methods 0.000 description 2 230000002860 competitive effect Effects 0.000 description 2 208000029078 coronary artery disease Diseases 0.000 description 2 238000012937 correction Methods 0.000 description 2 WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 2 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2 MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2 ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2 NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2 230000006735 deficit Effects 0.000 description 2 230000001419 dependent effect Effects 0.000 description 2 238000007323 disproportionation reaction Methods 0.000 description 2 238000012377 drug delivery Methods 0.000 description 2 230000004064 dysfunction Effects 0.000 description 2 239000012039 electrophile Substances 0.000 description 2 238000011067 equilibration Methods 0.000 description 2 230000003203 everyday effect Effects 0.000 description 2 239000000945 filler Substances 0.000 description 2 230000006870 function Effects 0.000 description 2 239000000499 gel Substances 0.000 description 2 230000012010 growth Effects 0.000 description 2 125000001188 haloalkyl group Chemical group 0.000 description 2 229960002897 heparin Drugs 0.000 description 2 229920000669 heparin Polymers 0.000 description 2 238000007327 hydrogenolysis reaction Methods 0.000 description 2 238000003384 imaging method Methods 0.000 description 2 238000000338 in vitro Methods 0.000 description 2 238000001802 infusion Methods 0.000 description 2 150000002500 ions Chemical class 0.000 description 2 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2 239000008101 lactose Substances 0.000 description 2 210000004185 liver Anatomy 0.000 description 2 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2 159000000003 magnesium salts Chemical class 0.000 description 2 HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2 229910052943 magnesium sulfate Inorganic materials 0.000 description 2 238000013227 male C57BL/6J mice Methods 0.000 description 2 230000007246 mechanism Effects 0.000 description 2 239000002609 medium Substances 0.000 description 2 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2 QTKAQJWFVXPIFV-YFKPBYRVSA-N methyl (2r)-2-acetamido-3-sulfanylpropanoate Chemical compound COC(=O)[C@H](CS)NC(C)=O QTKAQJWFVXPIFV-YFKPBYRVSA-N 0.000 description 2 150000007522 mineralic acids Chemical class 0.000 description 2 208000012268 mitochondrial disease Diseases 0.000 description 2 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2 201000003645 multiple acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2 210000004165 myocardium Anatomy 0.000 description 2 KROHFNRTQBLLOZ-UHFFFAOYSA-N n-[2-(4-hydroxyphenyl)ethyl]-2-iodoacetamide Chemical compound OC1=CC=C(CCNC(=O)CI)C=C1 KROHFNRTQBLLOZ-UHFFFAOYSA-N 0.000 description 2 XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical group CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2 231100000252 nontoxic Toxicity 0.000 description 2 230000003000 nontoxic effect Effects 0.000 description 2 239000012038 nucleophile Substances 0.000 description 2 230000000269 nucleophilic effect Effects 0.000 description 2 238000001543 one-way ANOVA Methods 0.000 description 2 208000020911 optic nerve disease Diseases 0.000 description 2 230000003287 optical effect Effects 0.000 description 2 239000000825 pharmaceutical preparation Substances 0.000 description 2 NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2 239000010452 phosphate Substances 0.000 description 2 239000008055 phosphate buffer solution Substances 0.000 description 2 OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2 239000011574 phosphorus Substances 0.000 description 2 125000003367 polycyclic group Chemical group 0.000 description 2 238000010149 post-hoc-test Methods 0.000 description 2 239000011591 potassium Substances 0.000 description 2 229910052700 potassium Inorganic materials 0.000 description 2 GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2 238000012545 processing Methods 0.000 description 2 230000000644 propagated effect Effects 0.000 description 2 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2 238000010926 purge Methods 0.000 description 2 150000003242 quaternary ammonium salts Chemical class 0.000 description 2 230000002285 radioactive effect Effects 0.000 description 2 230000003578 releasing effect Effects 0.000 description 2 238000007363 ring formation reaction Methods 0.000 description 2 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2 230000011664 signaling Effects 0.000 description 2 229910052708 sodium Inorganic materials 0.000 description 2 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2 239000000600 sorbitol Substances 0.000 description 2 239000003381 stabilizer Substances 0.000 description 2 235000019698 starch Nutrition 0.000 description 2 238000003860 storage Methods 0.000 description 2 229960005322 streptomycin Drugs 0.000 description 2 235000000346 sugar Nutrition 0.000 description 2 PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2 230000004083 survival effect Effects 0.000 description 2 208000024891 symptom Diseases 0.000 description 2 239000011885 synergistic combination Substances 0.000 description 2 230000009885 systemic effect Effects 0.000 description 2 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 2 239000003826 tablet Substances 0.000 description 2 239000000454 talc Substances 0.000 description 2 229910052623 talc Inorganic materials 0.000 description 2 238000004809 thin layer chromatography Methods 0.000 description 2 125000003396 thiol group Chemical class [H]S* 0.000 description 2 VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2 125000004954 trialkylamino group Chemical group 0.000 description 2 230000001960 triggered effect Effects 0.000 description 2 229910052722 tritium Inorganic materials 0.000 description 2 DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2 239000003643 water by type Substances 0.000 description 2 LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1 GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1 DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1 KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1 IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1 JTPZTKBRUCILQD-UHFFFAOYSA-N 1-methylimidazolidin-2-one Chemical compound CN1CCNC1=O JTPZTKBRUCILQD-UHFFFAOYSA-N 0.000 description 1 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1 SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1 HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1 RYRPHZROJNDXEV-UHFFFAOYSA-N 2-tritylsulfanylacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCC(=O)O)C1=CC=CC=C1 RYRPHZROJNDXEV-UHFFFAOYSA-N 0.000 description 1 FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1 FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1 229960000549 4-dimethylaminophenol Drugs 0.000 description 1 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1 CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1 HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1 244000215068 Acacia senegal Species 0.000 description 1 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1 208000018126 Adrenomyeloneuropathy Diseases 0.000 description 1 229920001817 Agar Polymers 0.000 description 1 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1 GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1 USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1 239000005695 Ammonium acetate Substances 0.000 description 1 102000008873 Angiotensin II receptor Human genes 0.000 description 1 108050000824 Angiotensin II receptor Proteins 0.000 description 1 208000036640 Asperger disease Diseases 0.000 description 1 201000006062 Asperger syndrome Diseases 0.000 description 1 241000416162 Astragalus gummifer Species 0.000 description 1 206010003591 Ataxia Diseases 0.000 description 1 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1 206010003658 Atrial Fibrillation Diseases 0.000 description 1 208000020706 Autistic disease Diseases 0.000 description 1 201000005943 Barth syndrome Diseases 0.000 description 1 BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1 208000020925 Bipolar disease Diseases 0.000 description 1 241000283725 Bos Species 0.000 description 1 208000003174 Brain Neoplasms Diseases 0.000 description 1 ODUJDLDAARWHEZ-UHFFFAOYSA-N C(C)(=O)NC(C(SSC(N(CCCN(C(OC(C)(C)C)=O)C)C)=O)(C)C)C(=O)OC Chemical compound C(C)(=O)NC(C(SSC(N(CCCN(C(OC(C)(C)C)=O)C)C)=O)(C)C)C(=O)OC ODUJDLDAARWHEZ-UHFFFAOYSA-N 0.000 description 1 MRJAHPJAHNEXFH-UHFFFAOYSA-N C(C)(=O)NC(C(SSC(N(CCN(C(OC(C)(C)C)=O)C)C)=O)(C)C)C(=O)OC Chemical compound C(C)(=O)NC(C(SSC(N(CCN(C(OC(C)(C)C)=O)C)C)=O)(C)C)C(=O)OC MRJAHPJAHNEXFH-UHFFFAOYSA-N 0.000 description 1 229940127291 Calcium channel antagonist Drugs 0.000 description 1 241000282465 Canis Species 0.000 description 1 241000282472 Canis lupus familiaris Species 0.000 description 1 241001631457 Cannula Species 0.000 description 1 241000283707 Capra Species 0.000 description 1 OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1 BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1 206010007559 Cardiac failure congestive Diseases 0.000 description 1 208000024172 Cardiovascular disease Diseases 0.000 description 1 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 description 1 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 description 1 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 description 1 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 description 1 206010007687 Carotid artery stenosis Diseases 0.000 description 1 241000282693 Cercopithecidae Species 0.000 description 1 206010008025 Cerebellar ataxia Diseases 0.000 description 1 208000034710 Cerebral arteriovenous malformation Diseases 0.000 description 1 206010008120 Cerebral ischaemia Diseases 0.000 description 1 206010008479 Chest Pain Diseases 0.000 description 1 241000723346 Cinnamomum camphora Species 0.000 description 1 KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1 206010009895 Colitis ischaemic Diseases 0.000 description 1 206010010904 Convulsion Diseases 0.000 description 1 229920002261 Corn starch Polymers 0.000 description 1 208000021075 Creatine deficiency syndrome Diseases 0.000 description 1 102000004403 Cysteine-tRNA ligases Human genes 0.000 description 1 108090000918 Cysteine-tRNA ligases Proteins 0.000 description 1 FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1 RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1 108020004414 DNA Proteins 0.000 description 1 206010011878 Deafness Diseases 0.000 description 1 206010011903 Deafness traumatic Diseases 0.000 description 1 YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1 FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1 206010012689 Diabetic retinopathy Diseases 0.000 description 1 206010012742 Diarrhoea infectious Diseases 0.000 description 1 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1 240000001879 Digitalis lutea Species 0.000 description 1 SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1 201000010374 Down Syndrome Diseases 0.000 description 1 208000000059 Dyspnea Diseases 0.000 description 1 206010013975 Dyspnoeas Diseases 0.000 description 1 KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1 102000015782 Electron Transport Complex III Human genes 0.000 description 1 108010024882 Electron Transport Complex III Proteins 0.000 description 1 241000283074 Equus asinus Species 0.000 description 1 241000283073 Equus caballus Species 0.000 description 1 108090000371 Esterases Proteins 0.000 description 1 VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1 239000005977 Ethylene Substances 0.000 description 1 241000282324 Felis Species 0.000 description 1 241000282326 Felis catus Species 0.000 description 1 VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1 208000010412 Glaucoma Diseases 0.000 description 1 WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1 229920000084 Gum arabic Polymers 0.000 description 1 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1 239000012981 Hank's balanced salt solution Substances 0.000 description 1 206010019280 Heart failures Diseases 0.000 description 1 206010056328 Hepatic ischaemia Diseases 0.000 description 1 241001272567 Hominoidea Species 0.000 description 1 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 description 1 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 1 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 description 1 101000603761 Homo sapiens Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Proteins 0.000 description 1 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 description 1 229920001612 Hydroxyethyl starch Polymers 0.000 description 1 208000035150 Hypercholesterolemia Diseases 0.000 description 1 208000008454 Hyperhidrosis Diseases 0.000 description 1 208000031226 Hyperlipidaemia Diseases 0.000 description 1 208000001953 Hypotension Diseases 0.000 description 1 208000002263 Intracranial Arteriovenous Malformations Diseases 0.000 description 1 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1 XETQTCAMTVHYPO-UHFFFAOYSA-N Isocamphan von ungewisser Konfiguration Natural products C1CC2C(C)(C)C(C)C1C2 XETQTCAMTVHYPO-UHFFFAOYSA-N 0.000 description 1 208000025069 Juvenile Huntington disease Diseases 0.000 description 1 JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1 241000283953 Lagomorpha Species 0.000 description 1 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1 208000006136 Leigh Disease Diseases 0.000 description 1 208000017507 Leigh syndrome Diseases 0.000 description 1 241000283986 Lepus Species 0.000 description 1 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 1 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 1 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 1 235000019759 Maize starch Nutrition 0.000 description 1 241000124008 Mammalia Species 0.000 description 1 229930195725 Mannitol Natural products 0.000 description 1 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1 208000004535 Mesenteric Ischemia Diseases 0.000 description 1 208000001145 Metabolic Syndrome Diseases 0.000 description 1 AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1 208000034962 Methylmalonic acidemia with homocystinuria, type cblC Diseases 0.000 description 1 206010059521 Methylmalonic aciduria Diseases 0.000 description 1 206010059396 Mitochondrial DNA depletion Diseases 0.000 description 1 206010050029 Mitochondrial cytopathy Diseases 0.000 description 1 208000020128 Mitral stenosis Diseases 0.000 description 1 208000019022 Mood disease Diseases 0.000 description 1 208000026072 Motor neurone disease Diseases 0.000 description 1 208000001089 Multiple system atrophy Diseases 0.000 description 1 208000021642 Muscular disease Diseases 0.000 description 1 241000187479 Mycobacterium tuberculosis Species 0.000 description 1 201000009623 Myopathy Diseases 0.000 description 1 206010028851 Necrosis Diseases 0.000 description 1 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1 229910003849 O-Si Inorganic materials 0.000 description 1 APXQKUXXASCOHL-UHFFFAOYSA-N OC1=CC=C(C=C1)CCC(C(=O)N)N Chemical compound OC1=CC=C(C=C1)CCC(C(=O)N)N APXQKUXXASCOHL-UHFFFAOYSA-N 0.000 description 1 241000283973 Oryctolagus cuniculus Species 0.000 description 1 229910003872 O—Si Inorganic materials 0.000 description 1 102100035196 POLG alternative reading frame Human genes 0.000 description 1 208000002193 Pain Diseases 0.000 description 1 208000018737 Parkinson disease Diseases 0.000 description 1 208000013234 Pearson syndrome Diseases 0.000 description 1 241001494479 Pecora Species 0.000 description 1 108091005804 Peptidases Proteins 0.000 description 1 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 description 1 102000007456 Peroxiredoxin Human genes 0.000 description 1 208000012202 Pervasive developmental disease Diseases 0.000 description 1 241000288906 Primates Species 0.000 description 1 239000004365 Protease Substances 0.000 description 1 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 description 1 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 description 1 206010038540 Renal tubular necrosis Diseases 0.000 description 1 208000017442 Retinal disease Diseases 0.000 description 1 206010057430 Retinal injury Diseases 0.000 description 1 206010038910 Retinitis Diseases 0.000 description 1 208000007014 Retinitis pigmentosa Diseases 0.000 description 1 206010038923 Retinopathy Diseases 0.000 description 1 206010038933 Retinopathy of prematurity Diseases 0.000 description 1 208000006289 Rett Syndrome Diseases 0.000 description 1 208000036353 Rett disease Diseases 0.000 description 1 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1 241000283984 Rodentia Species 0.000 description 1 230000006295 S-nitrosylation Effects 0.000 description 1 241000854711 Shinkai Species 0.000 description 1 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1 XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1 229920002125 Sokalan® Polymers 0.000 description 1 CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1 229930006000 Sucrose Natural products 0.000 description 1 UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1 208000036064 Surgical Blood Loss Diseases 0.000 description 1 229920002253 Tannate Polymers 0.000 description 1 208000002903 Thalassemia Diseases 0.000 description 1 208000007536 Thrombosis Diseases 0.000 description 1 208000000323 Tourette Syndrome Diseases 0.000 description 1 208000016620 Tourette disease Diseases 0.000 description 1 229920001615 Tragacanth Polymers 0.000 description 1 208000032109 Transient ischaemic attack Diseases 0.000 description 1 208000030886 Traumatic Brain injury Diseases 0.000 description 1 DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1 206010044688 Trisomy 21 Diseases 0.000 description 1 241000251539 Vertebrata Species 0.000 description 1 GWZOLWLJEJRQMZ-UHFFFAOYSA-N [S].S Chemical compound [S].S GWZOLWLJEJRQMZ-UHFFFAOYSA-N 0.000 description 1 210000003489 abdominal muscle Anatomy 0.000 description 1 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1 208000004622 abetalipoproteinemia Diseases 0.000 description 1 230000002159 abnormal effect Effects 0.000 description 1 229940124532 absorption promoter Drugs 0.000 description 1 235000010489 acacia gum Nutrition 0.000 description 1 239000000205 acacia gum Substances 0.000 description 1 DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Chemical group CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1 150000001241 acetals Chemical group 0.000 description 1 150000001242 acetic acid derivatives Chemical class 0.000 description 1 DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1 239000003377 acid catalyst Substances 0.000 description 1 206010000891 acute myocardial infarction Diseases 0.000 description 1 125000002015 acyclic group Chemical group 0.000 description 1 125000004423 acyloxy group Chemical group 0.000 description 1 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1 239000000654 additive Substances 0.000 description 1 230000000996 additive effect Effects 0.000 description 1 239000002671 adjuvant Substances 0.000 description 1 230000001800 adrenalinergic effect Effects 0.000 description 1 239000000674 adrenergic antagonist Substances 0.000 description 1 230000002411 adverse Effects 0.000 description 1 239000008272 agar Substances 0.000 description 1 235000010419 agar Nutrition 0.000 description 1 229940040563 agaric acid Drugs 0.000 description 1 125000003172 aldehyde group Chemical group 0.000 description 1 150000001299 aldehydes Chemical class 0.000 description 1 235000010443 alginic acid Nutrition 0.000 description 1 239000000783 alginic acid Substances 0.000 description 1 229920000615 alginic acid Polymers 0.000 description 1 229960001126 alginic acid Drugs 0.000 description 1 150000004781 alginic acids Chemical class 0.000 description 1 125000004183 alkoxy alkyl group Chemical group 0.000 description 1 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1 125000004414 alkyl thio group Chemical group 0.000 description 1 125000005012 alkyl thioether group Chemical group 0.000 description 1 125000005237 alkyleneamino group Chemical group 0.000 description 1 125000005238 alkylenediamino group Chemical group 0.000 description 1 125000005282 allenyl group Chemical group 0.000 description 1 230000004075 alteration Effects 0.000 description 1 125000003368 amide group Chemical group 0.000 description 1 150000001408 amides Chemical class 0.000 description 1 125000004103 aminoalkyl group Chemical group 0.000 description 1 229910021529 ammonia Inorganic materials 0.000 description 1 229940043376 ammonium acetate Drugs 0.000 description 1 235000019257 ammonium acetate Nutrition 0.000 description 1 238000005915 ammonolysis reaction Methods 0.000 description 1 238000002399 angioplasty Methods 0.000 description 1 125000000129 anionic group Chemical group 0.000 description 1 230000008485 antagonism Effects 0.000 description 1 230000003466 anti-cipated effect Effects 0.000 description 1 239000003416 antiarrhythmic agent Substances 0.000 description 1 239000003529 anticholesteremic agent Substances 0.000 description 1 229940127226 anticholesterol agent Drugs 0.000 description 1 239000003146 anticoagulant agent Substances 0.000 description 1 229940127219 anticoagulant drug Drugs 0.000 description 1 230000003078 antioxidant effect Effects 0.000 description 1 229940127218 antiplatelet drug Drugs 0.000 description 1 125000003435 aroyl group Chemical group 0.000 description 1 125000005239 aroylamino group Chemical group 0.000 description 1 201000000034 arteriovenous malformations of the brain Diseases 0.000 description 1 210000001367 artery Anatomy 0.000 description 1 125000005251 aryl acyl group Chemical group 0.000 description 1 125000004659 aryl alkyl thio group Chemical group 0.000 description 1 125000001769 aryl amino group Chemical group 0.000 description 1 125000005110 aryl thio group Chemical group 0.000 description 1 125000005165 aryl thioxy group Chemical group 0.000 description 1 125000000732 arylene group Chemical group 0.000 description 1 238000003556 assay Methods 0.000 description 1 230000002238 attenuated effect Effects 0.000 description 1 230000004888 barrier function Effects 0.000 description 1 230000009286 beneficial effect Effects 0.000 description 1 229940077388 benzenesulfonate Drugs 0.000 description 1 SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1 150000001558 benzoic acid derivatives Chemical class 0.000 description 1 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1 235000019445 benzyl alcohol Nutrition 0.000 description 1 239000002876 beta blocker Substances 0.000 description 1 239000011230 binding agent Substances 0.000 description 1 238000002306 biochemical method Methods 0.000 description 1 239000012472 biological sample Substances 0.000 description 1 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1 230000037396 body weight Effects 0.000 description 1 229930006742 bornane Natural products 0.000 description 1 210000005013 brain tissue Anatomy 0.000 description 1 125000001246 bromo group Chemical group Br* 0.000 description 1 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1 239000000480 calcium channel blocker Substances 0.000 description 1 229930008380 camphor Natural products 0.000 description 1 229960000846 camphor Drugs 0.000 description 1 MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1 150000004657 carbamic acid derivatives Chemical class 0.000 description 1 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1 125000005587 carbonate group Chemical group 0.000 description 1 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1 239000008112 carboxymethyl-cellulose Substances 0.000 description 1 229940105329 carboxymethylcellulose Drugs 0.000 description 1 230000000747 cardiac effect Effects 0.000 description 1 238000007675 cardiac surgery Methods 0.000 description 1 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 description 1 208000006170 carotid stenosis Diseases 0.000 description 1 238000006555 catalytic reaction Methods 0.000 description 1 210000000170 cell membrane Anatomy 0.000 description 1 238000003570 cell viability assay Methods 0.000 description 1 230000005754 cellular signaling Effects 0.000 description 1 239000001913 cellulose Substances 0.000 description 1 229920002678 cellulose Polymers 0.000 description 1 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 description 1 206010008118 cerebral infarction Diseases 0.000 description 1 230000008859 change Effects 0.000 description 1 238000012512 characterization method Methods 0.000 description 1 125000003636 chemical group Chemical group 0.000 description 1 239000003638 chemical reducing agent Substances 0.000 description 1 239000012069 chiral reagent Substances 0.000 description 1 125000001309 chloro group Chemical group Cl* 0.000 description 1 HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1 230000002057 chronotropic effect Effects 0.000 description 1 235000019504 cigarettes Nutrition 0.000 description 1 HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1 150000001860 citric acid derivatives Chemical class 0.000 description 1 208000035110 classic form autosomal dominant optic atrophy Diseases 0.000 description 1 ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1 238000002648 combination therapy Methods 0.000 description 1 230000000052 comparative effect Effects 0.000 description 1 230000001010 compromised effect Effects 0.000 description 1 230000001143 conditioned effect Effects 0.000 description 1 239000000039 congener Substances 0.000 description 1 238000013270 controlled release Methods 0.000 description 1 238000007796 conventional method Methods 0.000 description 1 238000007887 coronary angioplasty Methods 0.000 description 1 230000009260 cross reactivity Effects 0.000 description 1 239000012043 crude product Substances 0.000 description 1 125000006165 cyclic alkyl group Chemical group 0.000 description 1 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1 125000002993 cycloalkylene group Chemical group 0.000 description 1 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1 125000004956 cyclohexylene group Chemical group 0.000 description 1 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1 231100000433 cytotoxic Toxicity 0.000 description 1 230000001472 cytotoxic effect Effects 0.000 description 1 230000007547 defect Effects 0.000 description 1 230000002950 deficient Effects 0.000 description 1 238000010511 deprotection reaction Methods 0.000 description 1 238000001514 detection method Methods 0.000 description 1 238000001784 detoxification Methods 0.000 description 1 229910052805 deuterium Inorganic materials 0.000 description 1 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1 150000004985 diamines Chemical class 0.000 description 1 208000013219 diaphoresis Diseases 0.000 description 1 AFZSMODLJJCVPP-UHFFFAOYSA-N dibenzothiazol-2-yl disulfide Chemical compound C1=CC=C2SC(SSC=3SC4=CC=CC=C4N=3)=NC2=C1 AFZSMODLJJCVPP-UHFFFAOYSA-N 0.000 description 1 ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1 238000007865 diluting Methods 0.000 description 1 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1 239000001177 diphosphate Substances 0.000 description 1 XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1 235000011180 diphosphates Nutrition 0.000 description 1 239000006185 dispersion Substances 0.000 description 1 238000004090 dissolution Methods 0.000 description 1 238000009826 distribution Methods 0.000 description 1 125000002228 disulfide group Chemical group 0.000 description 1 239000002934 diuretic Substances 0.000 description 1 230000001882 diuretic effect Effects 0.000 description 1 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1 231100000673 dose–response relationship Toxicity 0.000 description 1 208000001848 dysentery Diseases 0.000 description 1 229940009662 edetate Drugs 0.000 description 1 230000002526 effect on cardiovascular system Effects 0.000 description 1 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1 229950005627 embonate Drugs 0.000 description 1 230000007613 environmental effect Effects 0.000 description 1 206010015037 epilepsy Diseases 0.000 description 1 150000002148 esters Chemical class 0.000 description 1 229950000206 estolate Drugs 0.000 description 1 CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1 YFXCNIVBAVFOBX-UHFFFAOYSA-N ethenylboronic acid Chemical compound OB(O)C=C YFXCNIVBAVFOBX-UHFFFAOYSA-N 0.000 description 1 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1 230000007717 exclusion Effects 0.000 description 1 230000029142 excretion Effects 0.000 description 1 238000013265 extended release Methods 0.000 description 1 206010016256 fatigue Diseases 0.000 description 1 239000010685 fatty oil Substances 0.000 description 1 230000001605 fetal effect Effects 0.000 description 1 239000003527 fibrinolytic agent Substances 0.000 description 1 239000003269 fluorescent indicator Substances 0.000 description 1 239000011888 foil Substances 0.000 description 1 230000037406 food intake Effects 0.000 description 1 229940050411 fumarate Drugs 0.000 description 1 VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1 230000002496 gastric effect Effects 0.000 description 1 210000001035 gastrointestinal tract Anatomy 0.000 description 1 238000007429 general method Methods 0.000 description 1 208000005017 glioblastoma Diseases 0.000 description 1 229960001731 gluceptate Drugs 0.000 description 1 KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1 229940050410 gluconate Drugs 0.000 description 1 229930195712 glutamate Natural products 0.000 description 1 229940049906 glutamate Drugs 0.000 description 1 235000013922 glutamic acid Nutrition 0.000 description 1 239000004220 glutamic acid Substances 0.000 description 1 239000008187 granular material Substances 0.000 description 1 238000000227 grinding Methods 0.000 description 1 150000004820 halides Chemical class 0.000 description 1 125000003106 haloaryl group Chemical group 0.000 description 1 231100000888 hearing loss Toxicity 0.000 description 1 230000010370 hearing loss Effects 0.000 description 1 208000016354 hearing loss disease Diseases 0.000 description 1 208000019622 heart disease Diseases 0.000 description 1 208000034737 hemoglobinopathy Diseases 0.000 description 1 125000004446 heteroarylalkyl group Chemical group 0.000 description 1 125000005549 heteroarylene group Chemical group 0.000 description 1 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1 125000006588 heterocycloalkylene group Chemical group 0.000 description 1 125000006038 hexenyl group Chemical group 0.000 description 1 125000005980 hexynyl group Chemical group 0.000 description 1 230000003054 hormonal effect Effects 0.000 description 1 XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1 150000003840 hydrochlorides Chemical class 0.000 description 1 XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1 230000007062 hydrolysis Effects 0.000 description 1 238000006460 hydrolysis reaction Methods 0.000 description 1 230000002209 hydrophobic effect Effects 0.000 description 1 125000002768 hydroxyalkyl group Chemical group 0.000 description 1 229940050526 hydroxyethylstarch Drugs 0.000 description 1 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1 UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1 125000002632 imidazolidinyl group Chemical group 0.000 description 1 125000002636 imidazolinyl group Chemical group 0.000 description 1 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1 230000000968 intestinal effect Effects 0.000 description 1 210000000936 intestine Anatomy 0.000 description 1 230000003834 intracellular effect Effects 0.000 description 1 238000007917 intracranial administration Methods 0.000 description 1 238000007918 intramuscular administration Methods 0.000 description 1 238000007912 intraperitoneal administration Methods 0.000 description 1 238000007919 intrasynovial administration Methods 0.000 description 1 238000007913 intrathecal administration Methods 0.000 description 1 238000001990 intravenous administration Methods 0.000 description 1 238000010253 intravenous injection Methods 0.000 description 1 238000007914 intraventricular administration Methods 0.000 description 1 238000011835 investigation Methods 0.000 description 1 XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1 229940044173 iodine-125 Drugs 0.000 description 1 125000002346 iodo group Chemical group I* 0.000 description 1 230000001057 ionotropic effect Effects 0.000 description 1 208000023569 ischemic bowel disease Diseases 0.000 description 1 201000008222 ischemic colitis Diseases 0.000 description 1 SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1 230000000155 isotopic effect Effects 0.000 description 1 230000000366 juvenile effect Effects 0.000 description 1 150000002576 ketones Chemical class 0.000 description 1 208000017169 kidney disease Diseases 0.000 description 1 239000004922 lacquer Substances 0.000 description 1 229940001447 lactate Drugs 0.000 description 1 208000006443 lactic acidosis Diseases 0.000 description 1 229940099584 lactobionate Drugs 0.000 description 1 JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1 231100000518 lethal Toxicity 0.000 description 1 230000001665 lethal effect Effects 0.000 description 1 208000036546 leukodystrophy Diseases 0.000 description 1 201000002818 limb ischemia Diseases 0.000 description 1 150000002632 lipids Chemical class 0.000 description 1 239000008297 liquid dosage form Substances 0.000 description 1 229940057995 liquid paraffin Drugs 0.000 description 1 239000007791 liquid phase Substances 0.000 description 1 208000019423 liver disease Diseases 0.000 description 1 239000000314 lubricant Substances 0.000 description 1 210000004072 lung Anatomy 0.000 description 1 235000019359 magnesium stearate Nutrition 0.000 description 1 229940049920 malate Drugs 0.000 description 1 VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1 150000002688 maleic acid derivatives Chemical class 0.000 description 1 BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1 210000004962 mammalian cell Anatomy 0.000 description 1 IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1 239000000594 mannitol Substances 0.000 description 1 235000010355 mannitol Nutrition 0.000 description 1 238000001819 mass spectrum Methods 0.000 description 1 230000004060 metabolic process Effects 0.000 description 1 AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1 HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1 KEWQCDSNXAVAMG-UHFFFAOYSA-N methyl 2-acetamido-3-methyl-3-[[methyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]carbamoyl]disulfanyl]butanoate Chemical compound C(C)(=O)NC(C(SSC(N(CCNC(OC(C)(C)C)=O)C)=O)(C)C)C(=O)OC KEWQCDSNXAVAMG-UHFFFAOYSA-N 0.000 description 1 NDTGSGSEKDKPNP-UHFFFAOYSA-N methyl 2-acetamido-3-methyl-3-[[methyl-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]carbamoyl]disulfanyl]butanoate Chemical compound C(C)(=O)NC(C(SSC(N(CCCNC(OC(C)(C)C)=O)C)=O)(C)C)C(=O)OC NDTGSGSEKDKPNP-UHFFFAOYSA-N 0.000 description 1 229920000609 methyl cellulose Polymers 0.000 description 1 239000001923 methylcellulose Substances 0.000 description 1 235000010981 methylcellulose Nutrition 0.000 description 1 201000003694 methylmalonic acidemia Diseases 0.000 description 1 201000007998 methylmalonic aciduria and homocystinuria type cblC Diseases 0.000 description 1 GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1 230000002438 mitochondrial effect Effects 0.000 description 1 208000006887 mitral valve stenosis Diseases 0.000 description 1 125000002950 monocyclic group Chemical group 0.000 description 1 125000006682 monohaloalkyl group Chemical group 0.000 description 1 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1 125000002757 morpholinyl group Chemical group 0.000 description 1 208000005264 motor neuron disease Diseases 0.000 description 1 201000006417 multiple sclerosis Diseases 0.000 description 1 210000003205 muscle Anatomy 0.000 description 1 201000006938 muscular dystrophy Diseases 0.000 description 1 230000035772 mutation Effects 0.000 description 1 230000003680 myocardial damage Effects 0.000 description 1 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1 230000017074 necrotic cell death Effects 0.000 description 1 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1 230000001537 neural effect Effects 0.000 description 1 208000015122 neurodegenerative disease Diseases 0.000 description 1 201000001119 neuropathy Diseases 0.000 description 1 230000007823 neuropathy Effects 0.000 description 1 238000006386 neutralization reaction Methods 0.000 description 1 150000002823 nitrates Chemical class 0.000 description 1 125000006574 non-aromatic ring group Chemical group 0.000 description 1 231100000956 nontoxicity Toxicity 0.000 description 1 125000005485 noradamantyl group Chemical group 0.000 description 1 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1 QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 1 239000000162 organ preservation solution Substances 0.000 description 1 239000003960 organic solvent Substances 0.000 description 1 239000003791 organic solvent mixture Substances 0.000 description 1 238000007254 oxidation reaction Methods 0.000 description 1 125000004043 oxo group Chemical group O=* 0.000 description 1 238000001139 pH measurement Methods 0.000 description 1 238000004806 packaging method and process Methods 0.000 description 1 229910052763 palladium Inorganic materials 0.000 description 1 229940014662 pantothenate Drugs 0.000 description 1 235000019161 pantothenic acid Nutrition 0.000 description 1 239000011713 pantothenic acid Substances 0.000 description 1 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1 125000005981 pentynyl group Chemical group 0.000 description 1 208000033808 peripheral neuropathy Diseases 0.000 description 1 150000002978 peroxides Chemical class 0.000 description 1 108030002458 peroxiredoxin Proteins 0.000 description 1 229940097156 peroxyl Drugs 0.000 description 1 239000003208 petroleum Substances 0.000 description 1 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1 UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1 UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1 230000000704 physical effect Effects 0.000 description 1 238000013031 physical testing Methods 0.000 description 1 239000002504 physiological saline solution Substances 0.000 description 1 239000000049 pigment Substances 0.000 description 1 239000006187 pill Substances 0.000 description 1 125000004193 piperazinyl group Chemical group 0.000 description 1 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1 125000003386 piperidinyl group Chemical group 0.000 description 1 210000002381 plasma Anatomy 0.000 description 1 239000004014 plasticizer Substances 0.000 description 1 231100000572 poisoning Toxicity 0.000 description 1 230000000607 poisoning effect Effects 0.000 description 1 239000002798 polar solvent Substances 0.000 description 1 125000006684 polyhaloalkyl group Polymers 0.000 description 1 231100000683 possible toxicity Toxicity 0.000 description 1 230000004481 post-translational protein modification Effects 0.000 description 1 239000012286 potassium permanganate Substances 0.000 description 1 229920001592 potato starch Polymers 0.000 description 1 229940069328 povidone Drugs 0.000 description 1 239000003755 preservative agent Substances 0.000 description 1 230000003244 pro-oxidative effect Effects 0.000 description 1 230000008569 process Effects 0.000 description 1 201000002212 progressive supranuclear palsy Diseases 0.000 description 1 WGYKZJWCGVVSQN-UHFFFAOYSA-O propan-1-aminium Chemical compound CCC[NH3+] WGYKZJWCGVVSQN-UHFFFAOYSA-O 0.000 description 1 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1 238000011321 prophylaxis Methods 0.000 description 1 125000006308 propyl amino group Chemical group 0.000 description 1 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1 QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1 230000002685 pulmonary effect Effects 0.000 description 1 238000000746 purification Methods 0.000 description 1 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1 125000003373 pyrazinyl group Chemical group 0.000 description 1 125000003072 pyrazolidinyl group Chemical group 0.000 description 1 125000002755 pyrazolinyl group Chemical group 0.000 description 1 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1 125000000719 pyrrolidinyl group Chemical group 0.000 description 1 125000001422 pyrrolinyl group Chemical group 0.000 description 1 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 description 1 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 description 1 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1 239000012048 reactive intermediate Substances 0.000 description 1 239000003087 receptor blocking agent Substances 0.000 description 1 230000001105 regulatory effect Effects 0.000 description 1 201000010384 renal tubular acidosis Diseases 0.000 description 1 230000008439 repair process Effects 0.000 description 1 239000013557 residual solvent Substances 0.000 description 1 230000035806 respiratory chain Effects 0.000 description 1 238000012552 review Methods 0.000 description 1 229940100486 rice starch Drugs 0.000 description 1 125000006413 ring segment Chemical group 0.000 description 1 YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1 229960001860 salicylate Drugs 0.000 description 1 229930195734 saturated hydrocarbon Natural products 0.000 description 1 201000000980 schizophrenia Diseases 0.000 description 1 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1 230000000276 sedentary effect Effects 0.000 description 1 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1 208000013220 shortness of breath Diseases 0.000 description 1 208000007056 sickle cell anemia Diseases 0.000 description 1 239000010703 silicon Substances 0.000 description 1 DRNXZGJGRSUXHW-UHFFFAOYSA-N silyl carbamate Chemical class NC(=O)O[SiH3] DRNXZGJGRSUXHW-UHFFFAOYSA-N 0.000 description 1 238000009097 single-agent therapy Methods 0.000 description 1 210000002027 skeletal muscle Anatomy 0.000 description 1 239000002002 slurry Substances 0.000 description 1 230000000391 smoking effect Effects 0.000 description 1 235000010413 sodium alginate Nutrition 0.000 description 1 239000000661 sodium alginate Substances 0.000 description 1 229940005550 sodium alginate Drugs 0.000 description 1 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1 239000007901 soft capsule Substances 0.000 description 1 239000007909 solid dosage form Substances 0.000 description 1 239000012439 solid excipient Substances 0.000 description 1 230000003381 solubilizing effect Effects 0.000 description 1 238000001179 sorption measurement Methods 0.000 description 1 125000006850 spacer group Chemical group 0.000 description 1 208000002320 spinal muscular atrophy Diseases 0.000 description 1 239000007921 spray Substances 0.000 description 1 239000008107 starch Substances 0.000 description 1 239000007858 starting material Substances 0.000 description 1 210000002784 stomach Anatomy 0.000 description 1 230000035882 stress Effects 0.000 description 1 238000007920 subcutaneous administration Methods 0.000 description 1 150000003890 succinate salts Chemical class 0.000 description 1 KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1 239000005720 sucrose Substances 0.000 description 1 150000008163 sugars Chemical class 0.000 description 1 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1 BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1 150000003457 sulfones Chemical class 0.000 description 1 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1 150000003462 sulfoxides Chemical class 0.000 description 1 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1 239000013589 supplement Substances 0.000 description 1 239000000725 suspension Substances 0.000 description 1 208000011580 syndromic disease Diseases 0.000 description 1 239000006188 syrup Substances 0.000 description 1 235000020357 syrup Nutrition 0.000 description 1 238000007910 systemic administration Methods 0.000 description 1 235000012222 talc Nutrition 0.000 description 1 229940095064 tartrate Drugs 0.000 description 1 150000003892 tartrate salts Chemical class 0.000 description 1 229950002757 teoclate Drugs 0.000 description 1 GKWGBMHXVRSFRT-UHFFFAOYSA-N tert-butyl n-[2-(methylamino)ethyl]carbamate Chemical compound CNCCNC(=O)OC(C)(C)C GKWGBMHXVRSFRT-UHFFFAOYSA-N 0.000 description 1 YIMSPDZAVBIXRT-UHFFFAOYSA-N tert-butyl n-[3-(methylamino)propyl]carbamate Chemical compound CNCCCNC(=O)OC(C)(C)C YIMSPDZAVBIXRT-UHFFFAOYSA-N 0.000 description 1 QRXUKURKZNOVAF-UHFFFAOYSA-N tert-butyl n-methyl-n-[3-(methylamino)propyl]carbamate Chemical compound CNCCCN(C)C(=O)OC(C)(C)C QRXUKURKZNOVAF-UHFFFAOYSA-N 0.000 description 1 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1 CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1 238000002560 therapeutic procedure Methods 0.000 description 1 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1 150000007944 thiolates Chemical class 0.000 description 1 125000004568 thiomorpholinyl group Chemical group 0.000 description 1 229960000103 thrombolytic agent Drugs 0.000 description 1 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1 230000000451 tissue damage Effects 0.000 description 1 231100000827 tissue damage Toxicity 0.000 description 1 239000004408 titanium dioxide Substances 0.000 description 1 230000000699 topical effect Effects 0.000 description 1 231100000331 toxic Toxicity 0.000 description 1 231100000167 toxic agent Toxicity 0.000 description 1 230000002588 toxic effect Effects 0.000 description 1 239000003440 toxic substance Substances 0.000 description 1 238000012546 transfer Methods 0.000 description 1 230000009261 transgenic effect Effects 0.000 description 1 201000010875 transient cerebral ischemia Diseases 0.000 description 1 230000008733 trauma Effects 0.000 description 1 230000009529 traumatic brain injury Effects 0.000 description 1 125000006168 tricyclic group Chemical group 0.000 description 1 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1 WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1 229960003732 tyramine Drugs 0.000 description 1 238000004704 ultra performance liquid chromatography Methods 0.000 description 1 125000004417 unsaturated alkyl group Chemical group 0.000 description 1 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1 XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1 230000006442 vascular tone Effects 0.000 description 1 229940124549 vasodilator Drugs 0.000 description 1 239000003071 vasodilator agent Substances 0.000 description 1 PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1 238000003026 viability measurement method Methods 0.000 description 1 238000012800 visualization Methods 0.000 description 1 229940100445 wheat starch Drugs 0.000 description 1 Images Classifications C—CHEMISTRY
